Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: The JAK2 pathway is activated in idiopathic pulmonary fibrosis

Fig. 4

Fibroblast migration and proliferation in IPF were dependent on JAK2 and STAT3 activation. a, b Primary human fibroblasts from IPF patients were pre-treated for 30 min with 1 μM of the p-STAT3 inhibitor 5,15 DPP, the p-JAK2 inhibitor NSC33994, or the dual p-JAK2/p-STAT3 inhibitor JSI-124 and then cell migration was assessed. A scrape-wound was created by using a sterile p200 pipette tip to make a perpendicular linear scratch in the culture. After the cells had been washed, culture medium with or without pharmacologic modulators and IL-6/IL-13 was added. The size of the wound remaining was analyzed at the indicated times and expressed as a percentage of the initial wound area. c Fibroblast proliferation during 48 h was evaluated by the BrdU assay. Different JAK2 and STAT3 inhibitors were added 30 min before 10% fetal bovine serum (FBS) or (c) 50 ng IL-6/IL-13/mL (d) was added as the stimulus. Values are expressed as relative absorbance (450 nm) units. The results are expressed as the mean (SEM) of n = 4 (cells from four IPF patients) experiments per condition. Two-way ANOVA followed by post-hoc Bonferroni tests. *P < 0.05 vs. the solvent controls; #P < 0.05 vs. IL-6/IL-13 or 10% FBS; ┴ P < 0.05 vs. 5,15 DPP or NSC33994

Back to article page